Qiuzhixia

1、 Educational Experience

l PhD, Pharmacokinetics, China Pharmaceutical University (2014)

l BS, Pharmacy, China Pharmaceutical University (2009)

2、 Working Experience

l Associate Professor, Department of pharmacology, China Pharmaceutical University (2020 - )

l Lecturer, Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University (2014 - 2019)

1. Shen, P.; Wang, Y.Z.; Jia, X.X.; Xu, P.F.; Qin, L.; Feng, X.; Li, Z.Y.*; Qiu, Z.X.*. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases. Eur J Med Chem. 2022;239:114551. (IF: 7.088)

2. Zhuang, Y.; Sun, Q.S.; Jing, T.; Liu, J.; Meng, H.T.; Cao, Y.Q.; Qiu, Z.X.*; Sun, J.E.*; Li, N.* Contributions of intestine and liver to the absorption and disposition of FZJ-003, a selective JAK1 inhibitor with structure modification of filgotinib. Eur J Pharm Sci. 2022;175:106211. (IF: 5.112)

3. Xu, P.F.; Shen, P.; Wang. H.; Qin, L.; Ren, J.; Sun, Q.S.; Ge, R.L.; Bian, J.L.; Zhong, Y.; Li, Z.Y.*; Wang, J.B.*; Qiu, Z.X.*. Discovery of imidazopyrrolopyridines derivatives as novel and selective inhibitors of JAK2. Eur J Med Chem. 2021;218:113394. (IF: 7.088)

4. Liu, Q.Y.; Zhuang, Y.; Song, X.R.; Niu, Q.; Sun, Q.S.; Li, X.N.; Li, N.; Liu, B.L.; Huang, F.*; Qiu, Z.X.*. Tanshinone IIA prevents LPS-induced inflammatory responses in mice via inactivation of succinate dehydrogenase in macrophages. Acta Pharmacol Sin. 2021;42:987-997. (IF: 7.169)

5. Sun, Q.S.; Niu, Q.; Guo, Y.T.; Zhuang, Y.; Li, X.N.; Liu, J.; Li, N.; Li, Z.Y.*; Huang, F.*; Qiu, Z.X.*. Regulation on Citrate Influx and Metabolism through Inhibiting SLC13A5 and ACLY: A Novel Mechanism Mediating the Therapeutic Effects of Curcumin on NAFLD. J Agric Food Chem. 2021;69:8714-8725. (IF: 5.895)

6. Chang, S.Q.; Wang, M.; Tian, Y.S.; Qi, J.*; Qiu, Z.X.*. Systematic analysis and identification of the absorption and metabolic components of Zengye decoction in type 2 diabetic rats by HPLC-ESI-Q-TOF-MS/MS. Chin Med. 2020;15:50. (IF: 5.451)

7. Qiu, Z.X.; Dong, J.J.; Xue, C.; Li, X.N.; Liu, K.; Liu, B.L.; Cheng, J.; Huang, F.* Liuwei Dihuang Pills alleviate the polycystic ovary syndrome with improved insulin sensitivity through PI3K/Akt signaling pathway. J Ethnopharmacol. 2020;250:111965, (IF: 5.195)

8. Qiu, Z.X.; Liu, Q.Y.  ; Yu, J.J.; Dai, Y ; Li, X.N.; Huang, F. *; Li, N*. Insulin resistance accelerated the clearance of resveratrol: A note of caution. J Funct Foods. 2019; 58:311-323 (IF：5.223)

9. Yu, J.J.; Liu, Q.Y.; Lu, X.Y.; Li, X.N.; Li, N.; Liu, B.L.; Huang, F.*; Qiu, Z.X.*. Inhibitory and inductive effects of Corydalis saxicola Bunting total alkaloids (CSBTA) on cytochrome P450s in rats. Phytother Res. 2018;32:1818-1827. (IF: 3.349)

Qiu, Z.X.; Zhang, S,H.; Li, A.Y.; Yu, J.J.; Li, N.; Huang, F.*; Liu, B.L.* The role of curcumin in disruption of HIF-1a accumulation to alleviate adipose fibrosis via AMPK-mediated mTOR pathway in high-fat diet fed mice. J Funct Foods. 2017;33:155-165. (IF: 3.197)

1. National Natural Science Foundation of China (surface project), 82274013, Combined inhibition of ACLY/ACSS2-acetyl-CoA pathways to reverse the development and progression of NAFLD, 2023/01-2026/12, $520,000, study in progress, Project Director

2. Fundamental Research Funds for the Central Universities (key project), 2632019ZD02, Targeting SDH to control HIF-1α and STAT2 to alleviate inflammation, 2019/01-2020/12, $150,000, study complete, Project Director

3. National Natural Science Foundation of China (youth project), 81503149, PK/PD model based on DAG-PKC system to investigate the novel strategy to predict and alleviate insulin resistance, 2016/01-2018/12, $180,000, study complete, Project Director

4. Natural Science Foundation of Jiangsu Province (youth project), SBK201240817,

Establish PK/PD model to investigate the mechanism of regulating lipolysis to improve gluconeogenesis and to predict insulin resistance, 2015/07-2018/06, $200,000, study complete, Project Director